Today is the inaugural day of a new format. Let me know how you like it:
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
AbbVie Press Release
-More bad news from the world of ADC.
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
Business Wire
-Exelixis is announcing that they are licensing the ICON-1 asset from Iconic Therapeutics targeting Tissue Factor in cancer cells.
SUN-174 Severe Insulin Resistance and Diabetic Ketoacidosis after Brentuximab Vendotin and Cyclosporin Treatment
Journal of the Endocrin Society
-Brentuximab vedotin induces full diabetic ketoacidosis episode in 23 year old patient. Take a second to realize how potent these molecules that we are dealing with actually are.
As Daiichi Sankyo-partnered breast cancer drug marches toward finish line, AstraZeneca brings in Canadian scientist Sunil Verma to rev up R&D
Endpoints News
- A massive $7 billion licensing agreement was only the start of a shake-up at AZ. Add in the removal of MedImmune as a separate entity and now a shakeup at the executive level. This is a pretty big reckoning for the guys and gals over there.
'Cornucopia' of biopharma innovation blurs drug launch forecasts, analyst laments
FiercePharma
- New technologies mean new cures, but the onslaught of completely new therapies also means increased uncertainty, and that results in higher prices. Pretty interesting stuff.
-
-
-
[Main]
No comments:
Post a Comment